Starting Off on the Right Foot - ACCESS Data Leads ADA First Presentations

Research evidence excerpt

Starting Off on the Right Foot - ACCESS Data Leads ADA First Presentations

June 5, 2026 | 15:28 ET~

Structure Therapeutics, Inc

GPCR-NSDQ Rating Price: Jun-4 Target Total Rtn Biotechnology

Outperform $39.06 $145.00 271%

Evan David Seigerman Analyst

evan.seigerman@bmo.com (212) 444-4328

Conor MacKay VP Associate

Starting Off on the Right Foot - ACCESS Data Leads conor.mackay@bmo.com (347) 988-4235

Malcolm Hoffman, CFA VP AssociateADA First Presentations

malcolm.hoffman@bmo.com (646) 438-2627

Bottom Line: Legal Entity: BMO Capital Markets Corp.

Kicking off ADA with presentation of Structure's ACCESS/ACCESS-OLE data

2YR Price Volume Chart

sets, reaffirming efficacy and safety. Data shared today continued to highlight 100

aleniglipron's potentially best-in-class oral small molecule weight loss profile. 9080

Commentary from the presenter underscored the durable weight loss, and clean safety 70

profile of the asset with no liver signals observed to date. More to come for Structure 50 30

later in the conference with data for aleniglipron in combination with its oral small 40 20 30

molecule amylin ACCG-2671 in non-human primates slated for Sunday's late-breaking 20 10

poster session (Abstract:3061-LB). 10 Dec Jun Dec Jun0

LHS: Price ($) / RHS: Volume (mm) Source: FactSet

Key Points Company Data in $

Dividend $0.00 Shares O/S (mm) 213.2Aleniglipron ACCESS data further confirms initial efficacy demonstrated in the top-

line and OLE data release. Kicking off the American Diabetes Association (ADA) 2026 Yield 0.0% Market Cap (mm) $2,776

conference, leading obesity therapeutic physician, Dr. Julio Rosenstock, reviewed full 52-Week High $95 52-Week Low $16

data from the ACCESS trial of aleniglipron in patients who are overweight/obese. While BMO Estimates in $